MERCK & CO., INC. (MRK)
FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer
📈 **POSITIVE** • High confidence analysis (83%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business